New Insights from cure hHT's cHORUS registry
“HHT is the second most common inherited bleeding disorder worldwide, with a major burden of chronic mucosal bleeding and high risks of intracranial and intrapulmonary hemorrhage. Chronic bleeding in HHT results in the highest burden of iron deficiency and iron deficiency anemia of any bleeding disorder, and progressively worsens over the lifespan in most patients. Proper management of chronic bleeding in HHT involves advanced iron replacement strategies, with intravenous iron product selection of critical importance, and use of systemic therapies to reduce bleeding burden and achieve hemostasis.”
– Dr Hanny Al-Samkari
“Clinical spectrum of hereditary hemorrhagic telangiectasia: data from the Comprehensive HHT Outcomes Registry of the US (CHORUS)” by Hanny Al-Samkari et al., published in Blood (2026) 148 (4): 417–432, is licensed under CC BY-NC-ND 4.0 licence. Original source available online at https://doi.org/10.1182/blood.2026033112. This document is shared without modifications.
Supplementary appendix to the publication
[pdf-embedder url=”https://bloodsa.org.za/wp-content/uploads/2026/08/blood_bld-2026-033112-mmc1-1.pdf” title=”blood_bld-2026-033112-mmc1″]Download
Blood Podcast Episode on the above publication – https://bloodpodcast.transistor.fm/episodes/148-4
Commentary on the publication posted in a recent issue of Blood – https://ashpublications.org/blood/article/148/4/391/569722/CHORUS-line-a-leg-up-for-HHT